1
|
Ostojić M, Đurić A, Živić K, Grahovac J. Analysis of the nischarin expression across human tumor types reveals its context-dependent role and a potential as a target for drug repurposing in oncology. PLoS One 2024; 19:e0299685. [PMID: 38781180 PMCID: PMC11115306 DOI: 10.1371/journal.pone.0299685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Accepted: 05/08/2024] [Indexed: 05/25/2024] Open
Abstract
Nischarin was reported to be a tumor suppressor that plays a critical role in breast cancer initiation and progression, and a positive prognostic marker in breast, ovarian and lung cancers. Our group has found that nischarin had positive prognostic value in female melanoma patients, but negative in males. This opened up a question whether nischarin has tumor type-specific and sex-dependent roles in cancer progression. In this study, we systematically examined in the public databases the prognostic value of nischarin in solid tumors, regulation of its expression and associated signaling pathways. We also tested the effects of a nischarin agonist rilmenidine on cancer cell viability in vitro. Nischarin expression was decreased in tumors compared to the respective healthy tissues, most commonly due to the deletions of the nischarin gene and promoter methylation. Unlike in healthy tissues where it was located in the cytoplasm and at the membrane, in tumor tissues nischarin could also be observed in the nuclei, implying that nuclear translocation may also account for its cancer-specific role. Surprisingly, in several cancer types high nischarin expression was a negative prognostic marker. Gene set enrichment analysis showed that in tumors in which high nischarin expression was a negative prognostic marker, signaling pathways that regulate stemness were enriched. In concordance with the findings that nischarin expression was negatively associated with pathways that control cancer growth and progression, nischarin agonist rilmenidine decreased the viability of cancer cells in vitro. Taken together, our study lays a ground for functional studies of nischarin in a context-dependent manner and, given that nischarin has several clinically approved agonists, provides rationale for their repurposing, at least in tumors in which nischarin is predicted to be a positive prognostic marker.
Collapse
Affiliation(s)
- Marija Ostojić
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Ana Đurić
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Kristina Živić
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| | - Jelena Grahovac
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
| |
Collapse
|
2
|
Yamano Y, Rakotondraibe HL. Understanding the Biosynthesis of Paxisterol in Lichen-Derived Penicillium aurantiacobrunneum for Production of Fluorinated Derivatives. Molecules 2022; 27:1641. [PMID: 35268742 PMCID: PMC8911623 DOI: 10.3390/molecules27051641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 02/23/2022] [Accepted: 02/28/2022] [Indexed: 11/16/2022] Open
Abstract
The U.S. endemic lichen (Niebla homalea)-derived Penicillium aurantiacobrunneum produced a cytotoxic paxisterol derivative named auransterol (2) and epi-citreoviridin (6). Feeding assay using 13C1-labelled sodium acetate not only produced C-13-labelled paxisterol but also confirmed the biosynthetic origin of the compound. The fluorination of bioactive compounds is known to improve pharmacological and pharmacokinetic effects. Our attempt to incorporate the fluorine atom in paxisterol and its derivatives using the fluorinated precursor sodium monofluoroacetate resulted in the isolation of 7-monofluoroacetyl paxisterol (7). The performed culture experiment, as well as the isolation and structure elucidation of the new fluorinated paxisterol, is discussed herein.
Collapse
Affiliation(s)
- Yoshi Yamano
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA;
- Graduate School of Biomedical and Health Sciences, Pharmaceutical Sciences, Hiroshima University, Hiroshima 739-8527, Japan
| | - Harinantenaina L. Rakotondraibe
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA;
- Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210, USA
- Center for Applied Plant Sciences, The Ohio State University, Columbus, OH 43210, USA
| |
Collapse
|
3
|
Micheli L, Di Cesare Mannelli L, Del Bello F, Giannella M, Piergentili A, Quaglia W, Carrino D, Pacini A, Ghelardini C. The Use of the Selective Imidazoline I 1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity. Neurotherapeutics 2020; 17:1005-1015. [PMID: 32572830 PMCID: PMC7609613 DOI: 10.1007/s13311-020-00873-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Anti-cancer therapy based on the repeated administration of oxaliplatin is limited by the development of a disabling neuropathic syndrome with detrimental effects on the patient's quality of life. The lack of effective pharmacological approaches calls for the identification of innovative therapeutic strategies based on new targets. We focused our attention on the imidazoline I1 receptor (I1-R) and in particular on the selective I1-R agonist 2-(1-([1,1'-biphenyl]-2-yl)propan-2-yl)-4,5-dihydro-1H-imidazole) (carbophenyline). The purpose of this work was the preclinical evaluation of the efficacy of carbophenyline on oxaliplatin-induced neuropathic pain in mice. Carbophenyline, acutely per os administered (0.1-10 mg kg-1), induced a dose-dependent anti-hyperalgesic effect that was completely blocked by the pre-treatment with the I1-R antagonist 3 or the I1/α2 receptor antagonist efaroxan, confirming the I1-R-dependent mechanism. Conversely, pre-treatment with the I2-R antagonist BU224 did not block the anti-nociceptive effect evoked by carbophenyline. Repeated oral administrations of carbophenyline (1 mg kg-1) for 14 days, starting from the first day of oxaliplatin injection, counteracted the development of neuropathic pain in all behavioral tests (cold plate, Von Frey, and paw pressure tests) carried out 24 h after the last carbophenyline treatment on days 7 and 14. In the dorsal horn of the spinal cord, carbophenyline significantly decreased the oxaliplatin-induced astrocyte activation detected by immunofluorescence staining by the specific labelling with GFAP antibody. In conclusion, carbophenyline showed anti-neuropathic properties both after acute and chronic treatment with preventive effect against oxaliplatin-induced astrocyte activation in the spinal cord. Therefore, I1-R agonists emerge as a new class of candidates for the management of oxaliplatin-induced neuropathic pain.
Collapse
Affiliation(s)
- Laura Micheli
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy
| | - Lorenzo Di Cesare Mannelli
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Alessandro Piergentili
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032, Camerino, Italy
| | - Donatello Carrino
- Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134, Florence, Italy
| | - Alessandra Pacini
- Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134, Florence, Italy
| | - Carla Ghelardini
- Dept. of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy
| |
Collapse
|
4
|
Ramesh M, Muthuraman A. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs. Comb Chem High Throughput Screen 2020; 23:887-897. [PMID: 32208114 DOI: 10.2174/1386207323666200324173231] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 01/20/2020] [Accepted: 02/04/2020] [Indexed: 11/22/2022]
Abstract
Monoamine oxidases are the crucial drug targets for the treatment of neurodegenerative disorders like depression, Parkinson's disease, and Alzheimer's disease. The enzymes catalyze the oxidative deamination of several monoamine containing neurotransmitters, i.e. serotonin (5-HT), melatonin, epinephrine, norepinephrine, phenylethylamine, benzylamine, dopamine, tyramine, etc. The oxidative reaction of monoamine oxidases results in the production of hydrogen peroxide that leads to the neurodegeneration process. Therefore, the inhibition of monoamine oxidases has shown a profound effect against neurodegenerative diseases. At present, the design and development of newer lead molecules for the inhibition of monoamine oxidases are under intensive research in the field of medicinal chemistry. Recently, the advancement in QSAR methodologies has shown considerable interest in the development of monoamine oxidase inhibitors. The present review describes the development of QSAR methodologies, and their role in the design of newer monoamine oxidase inhibitors. It will assist the medicinal chemist in the identification of selective and potent monoamine oxidase inhibitors from various chemical scaffolds.
Collapse
Affiliation(s)
- Muthusamy Ramesh
- Department of Pharmaceutical Analysis, Omega College of Pharmacy, Hyderabad-501 301, India
| | - Arunachalam Muthuraman
- Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia
| |
Collapse
|
5
|
Comparative pharmacodynamic analysis of imidazoline compounds using rat model of ocular mydriasis with a test of quantitative structure–activity relationships. J Pharm Biomed Anal 2017; 144:122-128. [DOI: 10.1016/j.jpba.2017.03.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/08/2017] [Accepted: 03/26/2017] [Indexed: 11/23/2022]
|
6
|
Giusepponi M, Cifani C, Micioni Di Bonaventura MV, Mattioli L, Hudson A, Diamanti E, Del Bello F, Giannella M, Mammoli V, Paoletti CD, Piergentili A, Pigini M, Quaglia W. Combined Interactions with I 1-, I 2-Imidazoline Binding Sites and α 2-Adrenoceptors To Manage Opioid Addiction. ACS Med Chem Lett 2016; 7:956-961. [PMID: 27774136 PMCID: PMC5066154 DOI: 10.1021/acsmedchemlett.6b00290] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 09/08/2016] [Indexed: 11/29/2022] Open
Abstract
Tolerance and dependence associated with chronic opioid exposure result from molecular, cellular, and neural network adaptations. Such adaptations concern opioid and nonopioid systems, including α2-adrenoceptors (α2-ARs) and I1- and I2-imidazoline binding sites (IBS). Agmatine, one of the hypothesized endogenous ligands of IBS, targeting several systems including α2-ARs and IBS, proved to be able to regulate opioid-induced analgesia and to attenuate the development of tolerance and dependence. Interested in the complex pharmacological profile of agmatine and considering the nature of its targets, we evaluated two series of imidazolines, rationally designed to simultaneously interact with I1-/I2-IBS or I1-/I2-IBS/α2-ARs. The compounds showing the highest affinities for I1-/I2-IBS or I1-/I2-IBS/α2-ARs have been selected for their in vivo evaluation on opiate withdrawal syndrome. Interestingly, 9, displaying I1-/I2-IBS/α2-ARs interaction profile, appears more effective in reducing expression and acquisition of morphine dependence and, therefore, might be considered a promising tool in managing opioid addiction.
Collapse
Affiliation(s)
- Maria
Elena Giusepponi
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Carlo Cifani
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | | | - Laura Mattioli
- School
of Pharmacy, Pharmacology Unit, University
of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Alan Hudson
- Department
of Pharmacology, Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Eleonora Diamanti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Mario Giannella
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Corinne Dalila Paoletti
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Alessandro Piergentili
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Maria Pigini
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School of
Pharmacy, Medicinal Chemistry Unit, University
of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| |
Collapse
|
7
|
Kornicka A, Wasilewska A, Sączewski J, Hudson AL, Boblewski K, Lehmann A, Gzella K, Belka M, Sączewski F, Gdaniec M, Rybczyńska A, Bączek T. 1-[(Imidazolidin-2-yl)imino]-1H-indoles as new hypotensive agents: synthesis andin vitroandin vivobiological studies. Chem Biol Drug Des 2016; 89:400-410. [DOI: 10.1111/cbdd.12846] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 07/13/2016] [Accepted: 08/19/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Anita Kornicka
- Department of Chemical Technology of Drugs; Medical University of Gdańsk; Gdańsk Poland
| | - Aleksandra Wasilewska
- Department of Chemical Technology of Drugs; Medical University of Gdańsk; Gdańsk Poland
| | - Jarosław Sączewski
- Department of Organic Chemistry; Medical University of Gdańsk; Gdańsk Poland
| | - Alan L. Hudson
- Department of Pharmacology; University of Alberta; Edmonton Canada
| | - Konrad Boblewski
- Department of Pathophysiology; Medical University of Gdańsk; Gdańsk Poland
| | - Artur Lehmann
- Department of Pathophysiology; Medical University of Gdańsk; Gdańsk Poland
| | - Karol Gzella
- Department of Chemical Technology of Drugs; Medical University of Gdańsk; Gdańsk Poland
| | - Mariusz Belka
- Department of Pharmaceutical Chemistry; Medical University of Gdańsk; Gdańsk Poland
| | - Franciszek Sączewski
- Department of Chemical Technology of Drugs; Medical University of Gdańsk; Gdańsk Poland
| | - Maria Gdaniec
- Faculty of Chemistry; A. Mickiewicz University; Poznań Poland
| | | | - Tomasz Bączek
- Department of Pharmaceutical Chemistry; Medical University of Gdańsk; Gdańsk Poland
| |
Collapse
|
8
|
Ramsay RR. Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol Psychiatry 2016; 69:81-9. [PMID: 26891670 DOI: 10.1016/j.pnpbp.2016.02.005] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Revised: 02/06/2016] [Accepted: 02/11/2016] [Indexed: 02/07/2023]
Abstract
Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their role in neurotransmitter breakdown. MAO B is the predominant form in glial cells and in platelets. MAO B structure, function and kinetics are described as a background for the effect of alterations in its activity on behavior. The need to inhibit MAO B to combat decreased brain amines continues to drive the search for new drugs. Reversible and irreversible inhibitors are now designed using data-mining, computational screening, docking and molecular dynamics. Multi-target ligands designed to combat the elevated activity of MAO B in Alzheimer's and Parkinson's Diseases incorporate MAO inhibition (usually irreversible) as well as iron chelation, antioxidant or neuroprotective properties. The main focus of drug design is the catalytic activity of MAO, but the imidazoline I2 site in the entrance cavity of MAO B is also a pharmacological target. Endogenous regulation of MAO B expression is discussed briefly in light of new studies measuring mRNA, protein, or activity in healthy and degenerative samples, including the effect of DNA methylation on the expression. Overall, this review focuses on examples of recent research on the molecular aspects of the expression, activity, and inhibition of MAO B.
Collapse
Affiliation(s)
- Rona R Ramsay
- Biomedical Sciences Research Complex, University of St Andrews, North Haugh, St Andrews KY16 9ST, United Kingdom.
| |
Collapse
|
9
|
Caprioli G, Mammoli V, Ricciutelli M, Sagratini G, Ubaldi M, Domi E, Mennuni L, Sabatini C, Galimberti C, Ferrari F, Milia C, Comi E, Lanza M, Giannella M, Pigini M, Del Bello F. Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation. Eur J Pharmacol 2015; 769:219-24. [PMID: 26593429 DOI: 10.1016/j.ejphar.2015.11.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 11/12/2015] [Accepted: 11/13/2015] [Indexed: 11/20/2022]
Abstract
Tolerance to opioid administration represents a serious medical alert in different chronic conditions. This study compares the effects of the imidazoline compounds 1, 2, and 3 on morphine tolerance in an animal model of inflammatory pain in the rat. 1, 2, and 3 have been selected in that, although bearing a common scaffold, preferentially bind to α2-adrenoceptors, imidazoline I2 receptors, or both systems, respectively. Such compounds have been tested in vivo by measuring the paw withdrawal threshold to mechanical pressure after complete Freund's adjuvant injection. To determine the ligand levels in rat plasma, an HPLC-mass spectrometry method has been developed. All the compounds significantly reduced the induction of morphine tolerance, showing different potency and duration of action. Indeed, the selective imidazoline I2 receptor interaction (2) restored the analgesic response by maintaining the same time-dependent profile observed after a single morphine administration. Differently, the selective α2C-adrenoceptor activation (1) or the combination between α2C-adrenoceptor activation and imidazoline I2 receptor engagement (3) promoted a change in the temporal profile of morphine analgesia by maintaining a mild but long lasting analgesic effect. Interestingly, the kinetics of compounds in rat plasma supported the pharmacodynamic data. Therefore, this study highlights that both peculiar biological profile and bioavailability of such ligands complement each other to modulate the reduction of morphine tolerance. Based on these observations, 1-3 can be considered useful leads in the design of new drugs able to turn off the undesired tolerance induced by opioids.
Collapse
Affiliation(s)
- Giovanni Caprioli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ricciutelli
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Gianni Sagratini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Massimo Ubaldi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Esi Domi
- School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032 Camerino, Italy
| | - Laura Mennuni
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Sabatini
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Galimberti
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Flora Ferrari
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Chiara Milia
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Eleonora Comi
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy; PhD program in Neuroscience, University of Milan-Bicocca, Italy
| | - Marco Lanza
- Department of Pharmacology & Toxicology, Rottapharm Biotech S.r.l., 20900 Monza, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
| | - Fabio Del Bello
- School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy.
| |
Collapse
|
10
|
Del Bello F, Bargelli V, Cifani C, Gratteri P, Bazzicalupi C, Diamanti E, Giannella M, Mammoli V, Matucci R, Micioni Di Bonaventura MV, Piergentili A, Quaglia W, Pigini M. Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation. ACS Med Chem Lett 2015; 6:496-501. [PMID: 26005521 DOI: 10.1021/acsmedchemlett.5b00115] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 04/03/2015] [Indexed: 01/25/2023] Open
Abstract
Pharmacological studies have suggested that I1-imidazoline receptors are involved in the regulation of cardiovascular function and that selective I1-agonists, devoid of the side effects associated with the common hypotensive α2-adrenoreceptor agonists, might be considered as a second generation of centrally acting antihypertensives. Therefore, in the present study, inspired by the antihypertensive behavior of our selective I1-agonist 4, we designed, prepared, and studied the novel analogues 5-9. A selective I1-profile, associated with significant hemodinamic effects, was displayed by 5, 8, and 9. Interestingly, the highest potency and longest lasting activity displayed by 8 (carbomethyline) suggested that van der Waals interactions, promoted by the ortho methyl decoration of its aromatic moiety, are particularly advantageous. In addition, in analogy to what was noted for (S)-(+)-4, the observation that only (S)-(+)-8 displayed significant hemodynamic effects unequivocally confirmed the stereospecific nature of the I1 proteins.
Collapse
Affiliation(s)
- Fabio Del Bello
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valentina Bargelli
- Department
NEUROFARBA, Preclinical and Clinical Pharmacology, University of Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Carlo Cifani
- School
of Pharmacy, Pharmacology Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Paola Gratteri
- Department NEUROFARBA, Pharmaceutical and Nutraceutical Section and Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino, Firenze, Italy
| | - Carla Bazzicalupi
- Department
of Chemistry Ugo Schiff, University of Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy
| | - Eleonora Diamanti
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Mario Giannella
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Rosanna Matucci
- Department
NEUROFARBA, Preclinical and Clinical Pharmacology, University of Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | | | - Alessandro Piergentili
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| | - Maria Pigini
- School
of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino
1, 62032 Camerino, Italy
| |
Collapse
|
11
|
Gasparik V, Greney H, Schann S, Feldman J, Fellmann L, Ehrhardt JD, Bousquet P. Synthesis and Biological Evaluation of 2-Aryliminopyrrolidines as Selective Ligands for I1 Imidazoline Receptors: Discovery of New Sympatho-Inhibitory Hypotensive Agents with Potential Beneficial Effects in Metabolic Syndrome. J Med Chem 2014; 58:878-87. [DOI: 10.1021/jm501456p] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Vincent Gasparik
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Hugues Greney
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Stephan Schann
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Josiane Feldman
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Lyne Fellmann
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Jean-Daniel Ehrhardt
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| | - Pascal Bousquet
- Laboratoire
de Neurobiologie
et Pharmacologie Cardiovasculaire, Faculté de Médecine,
EA 7296, Fédération de Médecine Translationnelle, Université de Strasbourg, 11 rue Humann, 67000 Strasbourg, France
| |
Collapse
|
12
|
Abstract
The imidazoline I2 receptor ligand BU99006 binds to and attenuates effects mediated by I2 receptors in vitro, although its effects in vivo have not been studied previously. This study examined the effects of BU99006 in two behavioral assays in rats: hypothermia and 2-BFI discrimination. BU99006 (3.2-15 mg/kg, intraperitoneally) produced a dose-dependent hypothermic effect (rectal temperature), which was antagonized by the I2 receptor antagonist idazoxan. BU99006 (3.2 or 10 mg/kg administered 10 min or 2 h before the session, respectively) did not significantly alter hypothermia produced by the I2 receptor agonist 2-BFI (10 mg/kg). In rats discriminating 5.6 mg/kg 2-BFI, BU99006 (1.78-17.8 mg/kg, intraperitoneally) produced 40 and 82% responding on the 2-BFI-associated lever when it was administered immediately or 2 h before the test sessions, respectively. BU99006 enhanced the discriminative stimulus and rate-suppressing effects of 2-BFI. Collectively, these data suggest that BU99006 is an imidazoline I2 receptor agonist with no evidence of I2 receptor antagonism in rats.
Collapse
|
13
|
Gao Z, Zhang L, Sun Z, Yu H, Xiao Y, Guo H. DABCO-catalyzed [3 + 2] annulation of sulfamate-derived cyclic imines with isocyanoacetates: synthesis of sulfamate-fused 2-imidazoline. Org Biomol Chem 2014; 12:5691-7. [DOI: 10.1039/c4ob00840e] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
14
|
Nikolic K, Filipic S, Agbaba D, Stark H. Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities. CNS Neurosci Ther 2014; 20:613-23. [PMID: 24836924 DOI: 10.1111/cns.12279] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/07/2014] [Accepted: 04/07/2014] [Indexed: 01/01/2023] Open
Abstract
The histamine H3 receptor (H3 R) is an important modulator of numerous central control mechanisms. Novel lead optimizations for H3 R antagonists/inverse agonists involved studies of structure-activity relationships, cross-affinities, and pharmacokinetic properties of promising ligands. Blockade of inhibitory histamine H3 autoreceptors reinforces histaminergic transmission, while antagonism of H3 heteroreceptors accelerates the corticolimbic liberation of acetylcholine, norepinephrine, glutamate, dopamine, serotonin and gamma-aminobutyric acid (GABA). The H3 R positioned at numerous neurotransmission crossroads indicates therapeutic applications of small-molecule H3 R modulators in a number of psychiatric and neurodegenerative diseases with various clinical candidates available. Dual target drugs displaying H3 R antagonism/inverse agonism with inhibition of acetylcholine esterase (AChE), histamine N-methyltransferase (HMT), or serotonin transporter (SERT) are novel class of procognitive agents. Main chemical diversities, pharmacophores, and pharmacological profiles of procognitive agents acting as H3 R antagonists/inverse agonists and dual H3 R antagonists/inverse agonists with inhibiting activity on AChE, HMT, or SERT are highlighted here.
Collapse
Affiliation(s)
- Katarina Nikolic
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Belgrade, Belgrade, Serbia
| | | | | | | |
Collapse
|
15
|
Min JW, Peng BW, He X, Zhang Y, Li JX. Gender difference in epileptogenic effects of 2-BFI and BU224 in mice. Eur J Pharmacol 2013; 718:81-6. [PMID: 24055191 DOI: 10.1016/j.ejphar.2013.09.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2013] [Revised: 08/28/2013] [Accepted: 09/04/2013] [Indexed: 10/26/2022]
Abstract
Imidazoline I2 receptors are involved in pain modulation and psychiatric disorders and its ligands may represent a new therapeutic strategy against pain and depression. In particular, 2-BFI and BU224 are the two most widely studied I2 receptor ligands and have antinociceptive and antidepressant-like activities in rodents. However, little is known of the toxicological effects and potential gender differences of these I2 receptor ligands. This study examined the epileptogenic activities of 2-BFI and BU224 in male and female mice and also examined their underlying receptor mechanisms. 2-BFI (10-40 mg/kg, i.p.) and BU224 (10-40 mg/kg) produced epileptic seizures in a dose-related manner, as did the epileptogenic agent, pentylenetetrazole (PTZ, 15-60 mg/kg). However, female mice were significantly more sensitive than male mice in all the measures. The commonly used I2 receptor antagonist, idazoxan (10mg/kg), did not block the onset and magnitude of the epileptic seizures or lethality induced by 2-BFI and BU224. When studied in combination, PTZ potentiated the epileptogenic effect of 2-BFI and BU224. The lack of antagonism by idazoxan of the epileptogenic activities of 2-BFI and BU224 suggests that the epileptogenic effects of 2-BFI and BU224 are mediated by non-imidazoline I2 receptors and that I2 receptors remain a viable therapeutic target for neurological disorders such as pain.
Collapse
Affiliation(s)
- Jia-Wei Min
- Department of Physiology, School of Basic Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan, Hubei 430071, PR China
| | | | | | | | | |
Collapse
|
16
|
Del Bello F, Diamanti E, Giannella M, Mammoli V, Mattioli L, Titomanlio F, Piergentili A, Quaglia W, Lanza M, Sabatini C, Caselli G, Poggesi E, Pigini M. Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity. ACS Med Chem Lett 2013; 4:875-9. [PMID: 24900763 DOI: 10.1021/ml400232p] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Accepted: 07/22/2013] [Indexed: 01/22/2023] Open
Abstract
Opioid addiction is often characterized as a chronic relapsing condition due to the severe somatic and behavioral signs, associated with depressive disorders, triggered by opiate withdrawal. Since prolonged abstinence remains a major challenge, our interest has been addressed to such objective. Exploring multitarget interactions, the present investigation suggests that 3 or its (S)-enantiomer and 4, endowed with effective α2C-AR agonism/α2A-AR antagonism/5-HT1A-R agonism, or 7 and 9-11 producing efficacious α2C-AR agonism/α2A-AR antagonism/I2-IBS interaction might represent novel multifunctional tools potentially useful for reducing withdrawal syndrome and associated depression. Such agents, lacking in sedative side effects due to their α2A-AR antagonism, might afford an improvement over current therapies with clonidine-like drugs.
Collapse
Affiliation(s)
- Fabio Del Bello
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Eleonora Diamanti
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Mario Giannella
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Valerio Mammoli
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Laura Mattioli
- School of Pharmacy, Pharmacognosy
Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Federica Titomanlio
- School of Pharmacy, Pharmacognosy
Unit, University of Camerino, Via Madonna
delle Carceri 9, 62032 Camerino, Italy
| | - Alessandro Piergentili
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Wilma Quaglia
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| | - Marco Lanza
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Chiara Sabatini
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Gianfranco Caselli
- Pharmacology & Toxicology
Department, Rottapharm-Madaus, 20052 Monza,
Italy
| | - Elena Poggesi
- Recordati S.pA., Drug Discovery, Via Civitali 1, 20148 Milano, Italy
| | - Maria Pigini
- School of Pharmacy, Medicinal
Chemistry Unit, University of Camerino,
Via S. Agostino 1, 62032 Camerino, Italy
| |
Collapse
|
17
|
Yang F, Wang Z, Song F, Liu X, Lan J, You J. One-step synthesis of imidazoline-containing macrocycles and their complexation with fullerenes C60 and C70. Chem Commun (Camb) 2013; 49:5975-7. [DOI: 10.1039/c3cc42640h] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|